The present invention relates to a novel 3-hydroxypropionate-lactate block copolymer [P(3HP-b-LA)], and a method for preparing same, and more specifically, provides a method for preparing a 3-hydroxypropionate-lactate block copolymer, and a 3-hydroxypropionate-lactate block copolymer produced thereby, the method comprising: a first culture step in which, by using recombinant E. coli improved so as to be incapable of biosynthesizing lactic acid, P(3HP) is biosynthesized at the early stage of culturing by having glycerol as a carbon source and through 3-hydroxypropionate-generating genes and an enhanced PHA synthase; and a second culture step in which P(3HP) production is inhibited by using a carbon catabolic repression system for selectively introducing only glucose into E. coli when glycerol and glucose are supplied together as carbon sources, and in which polylactate is biosynthesized to an interrupted P(3HP) terminus by the enabling of the expression of a lactate synthase and a lactyl-CoA converting enzyme through an IPTG induction system.

Compositions comprising a rhodanese with a phosphate-binding motif and methods of detoxifying bacterial endotoxins with such compositions.

Provided are a novel 3-hydroxypropionate-lactate block copolymer [P(3HP-b-LA)], and a method for preparing same, comprising: a) transforming a recombinant microorganism modified to be incapable of biosynthesizing lactic acid with a vector including a 3-hydroxypropionyl-CoA biosynthesis gene and a polyhydroxyalkanoate (PHA) synthetase gene, and a vector including a lactate biosynthesis gene and a gene of an enzyme that converts lactate to lactyl-CoA; (b) synthesizing poly(3-hydroxypropionate) (P(3HP)) by culturing the recombinant microorganism using a glycerol as a carbon source; and (c) inhibiting P(3HP) production by adding IPTG and glucose, and biosynthesizing polylactate (PLA) at the end of P(3HP) synthesized in step (b) by enabling the expression of a lactate biosynthesis enzyme and an enzyme that converts lactate to lactyl-CoA. Also provided is a recombinant microorganism produced in step a).

Provided is a genetically engineered microorganism comprising expression of multiple CoA transferases conferring certain advantages, including increased product production and fermentation stability. Also provided is a method for increasing production of a product comprising culturing the genetically engineered microorganism in the presence of a gaseous substrate wherein the gaseous substrate may comprise a C1-carbon source comprising one or more of CO, CO.sub.2, and H.sub.2.

The present disclosure provides for novel metabolic pathways to increase acetone and isopropanol formation. More specifically, the present disclosure provides for a recombinant microorganism comprising a plurality of first native and/or heterologous enzymes that function in a first engineered metabolic pathway to convert fructose-6-phosphate to acetyl-CoA and acetate (e.g., phosphoketolase and acetate kinase), wherein the plurality of first native and/or heterologous enzymes is activated, upregulated, or overexpressed. The recombinant microorganism further comprises a plurality of second native and/or heterologous enzymes that function in a second engineered metabolic pathways to convert acetyl-CoA and acetate to isopropanol (e.g., thiolase, CoA transferase and acetoacetate decarboxylase), wherein the plurality of second native and/or heterologous enzymes is activated, upregulated, or overexpressed. Also provided are methods for making isopropanol or acetone using the recombinant microorganisms.

Methods of synthesizing chondroitin sulfate oligosaccharides are provided. Enzymatic schematic approaches to synthesizing structurally defined homogenous chondroitin sulfate oligosaccharides at high yields are provided. Synthetic chondroitin sulfate oligosaccharides ranging from 3-mers to 15-mers are provided.

Disclosed is the production by fermentation of poly D-lactic acid (PDLA) and poly L-lactic acid (PLLA). In particular, there is provided engineered (prokaryotic or eukaryotic) cells for the direct synthesis of PLLA polymers and engineered eukaryotic cells for the direct synthesis of PDLA polymers starting from a carbon source, including residual biomasses of the different production chains.

This document describes biochemical pathways for producing 7-aminoheptanoic acid using a β-ketoacyl synthase or a β-ketothiolase to form an N-acetyl-5-amino-3-oxopentanoyl-CoA intermediate. 7-aminoheptanoic acid can be enzymatically converted to pimelic acid, 7-hydroxyheptanoic acid, heptamethylenediamine or 1,7-heptanediol or corresponding salts thereof. This document also describes recombinant microorganisms producing 7-aminoheptanoic acid as well as pimelic acid, 7-hydroxyheptanoic acid, heptamethylenediamine and 1,7-heptanediol or corresponding salts thereof.

The present invention provides several non-naturally occurring sulfotransferase enzymes that have been engineered to react with aryl sulfate compounds as sulfo group donors, instead of the natural substrate 3′-phosphoadenosine 5′-phosphosulfate (PAPS), and with heparosan-based polysaccharides, particularly heparan sulfate, as sulfo group acceptors. Each of the engineered sulfotransferase enzymes have a biological activity characterized by the position within the heparosan-based polysaccharide that receives the sulfo group, including glucosaminyl N-sulfotransferase activity, hexuronyl 2-O sulfotransferase activity, glucosaminyl 6-O sulfotransferase activity, or glucosaminyl 3-O sulfotransferase activity. Methods of using the engineered sulfotransferases to produce sulfated heparosan-based polysaccharides, including polysaccharides having anticoagulant activity, are also provided.

The present invention provides several non-naturally occurring sulfotransferase enzymes that have been engineered to react with aryl sulfate compounds as sulfo group donors, instead of the natural substrate 3′-phosphoadenosine 5′-phosphosulfate (PAPS), and with heparosan-based polysaccharides, particularly heparan sulfate, as sulfo group acceptors. Each of the engineered sulfotransferase enzymes have a biological activity characterized by the position within the heparosan-based polysaccharide that receives the sulfo group, including glucosaminyl N-sulfotransferase activity, hexuronyl 2-O sulfotransferase activity, glucosaminyl 6-O sulfotransferase activity, or glucosaminyl 3-O sulfotransferase activity. Methods of using the engineered sulfotransferases to produce sulfated heparosan-based polysaccharides, including polysaccharides having anticoagulant activity, are also provided.